Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30932969 | 0.96 | — | — | |
| SCHEMBL22288090 | 0.96 | — | — | |
| SCHEMBL22977551 | 0.92 | — | — | |
| SCHEMBL22977554 | 0.91 | RNASE1 (0.39) | RNASE1TOP2A | |
| SCHEMBL22288092 | 0.88 | — | — | |
| SCHEMBL30932973 | 0.88 | — | — | |
| SCHEMBL30932972 | 0.87 | RNASE1 (0.38) | RNASE1TOP2A | |
| SCHEMBL20535951 | 0.87 | RNASE1 (0.42) | RNASE1TOP2A | |
| SCHEMBL20535923 | 0.85 | RNASE1 (0.42) | RNASE1TOP2A | |
| SCHEMBL20535919 | 0.85 | RNASE1 (0.42) | RNASE1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
| WO-2019145713-A9 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | RNASE1 156/4885TOP2A 93/4885 |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TOP2A 96/4885 |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | RNASE1 156/4885TOP2A 93/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | RNASE1 70/4885TOP2A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.